Researchers at the Icahn School of Medicine at Mount Sinai have identified a previously hidden druggable site in a ...

• Establishing pharmacologically relevant exposure levels and engagement are two key steps in target validation. • There is a need for better biomarkers to objectively measure biological states and ...

Artificial intelligence (AI) is emerging as a transformative tool in drug discovery and development, influencing steps from target identification to clinical trial outcome analyses. Target ...

AI has attracted enormous investment across drug discovery, but major questions still remain around validation, ...

Accelerating Drug Discovery with AI and Next-Generation Automation The pharmaceutical industry is currently witnessi ...

Harbour BioMed and BioMap will build a globally leading AI-driven complex biologics AIDD infrastructure platform for ...

Drug development faces persistent challenges, with high attrition rates and unexpected adverse effects contributing to clinical trial failures. The recent convergence of large-scale biobanks, ...

A new study identified protein targets and drug candidates, including opportunities to repurpose existing drugs. Six key ...

Zhongyao Ma, PhD, holds a bachelor’s degree in biology from Shanghai Jiao Tong University and a PhD in genetics and developmental biology from the University of Georgia, U.S. His research focused on ...

Engitix is a biotechnology company focused on discovering and developing novel therapeutics by leveraging its proprietary extracellular matrix platform. By using human tissue-derived ECM Platform ...

Ibogaine’s unconventional “matrix pharmacology” may underlie both its therapeutic promise and unpredictable cardiac risks.

Smart multi-target drugs are reshaping modern therapeutics by addressing the complex, interconnected pathways that drive diseases like Alzheimer’s, cancer, and major depressive disorder. Advances in ...